Journal
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
Volume 23, Issue -, Pages 254-262Publisher
CELL PRESS
DOI: 10.1016/j.omtm.2021.08.009
Keywords
-
Categories
Funding
- Pfizer Inc.
Ask authors/readers for more resources
The study assessed various analytical techniques for quantifying capsid content and highlighted issues caused by empty capsids during the manufacturing process, emphasizing the need for better control and monitoring of empty capsids.
Adeno-associated virus (AAV) vectors, which contain a DNA transgene packaged into a protein capsid, have shown tremendous therapeutic potential in recent years. An inherent characteristic of the manufacturing process is production of empty capsids that lack the transgene and are therefore unable to provide the intended therapeutic benefit. The effect of empty capsids on clinical outcomes is not well understood, but there are immunogenicity and efficacy concerns, and these empty capsids are considered a product-related impurity. Therefore, empty capsids should be controlled during the manufacturing process and monitored through analytical testing, but there are limited techniques available that are capable of quantifying capsid content and even fewer that are amenable to validation and implementation as registered release tests in a regulated environment. In addition, there is currently not a widely accepted gold standard technique for quantifying capsid content, and the understanding of how the results compare between different orthogonal technologies is limited. The current study utilizes a comprehensive assessment to evaluate diverse analytical techniques for their ability to quantitate capsid content.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available